Cargando…
Prolonged humoral and cellular immunity in COVID-19-recovered patients()
By the beginning of 2021, the battle against coronavirus disease 2019 (COVID-19) remains ongoing. Investigating the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, in patients who have recovered from this disease could contribute...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040318/ https://www.ncbi.nlm.nih.gov/pubmed/33867805 http://dx.doi.org/10.1016/j.sjbs.2021.04.008 |
_version_ | 1783677762678030336 |
---|---|
author | Alsayb, May A. Alsamiri, Ali Dakhilallah D. Makhdoom, Hatem Q. Alwasaidi, Turki Osman, Haitham Mohammed Mahallawi, Waleed H. |
author_facet | Alsayb, May A. Alsamiri, Ali Dakhilallah D. Makhdoom, Hatem Q. Alwasaidi, Turki Osman, Haitham Mohammed Mahallawi, Waleed H. |
author_sort | Alsayb, May A. |
collection | PubMed |
description | By the beginning of 2021, the battle against coronavirus disease 2019 (COVID-19) remains ongoing. Investigating the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, in patients who have recovered from this disease could contribute to our understanding of the natural host immune response. We enrolled 38 participants in this study. 7 healthy participants and 31 COVID-19 patients who had recovered from COVID-19 and categorized them into 3 groups according to their previous clinical presentations: 10 moderate, 9 mild, and 12 asymptomatic. Flow cytometry analysis of peripheral lymphocyte counts in recovered patients showed significantly increased levels of CD4(+) T cells in patients with a history of mild and moderate COVID-19 symptoms compared with those healthy individuals (p < 0.05 and p < 0.0001 respectively). whereas no significant difference was observed in the CD8(+) T cell percentage in COVID-19-recovered patients compared with healthy individuals. Our study demonstrated that antibodies against the SARS-CoV-2 spike protein (anti-S) IgG antibody production could be observed in all recovered COVID-19 patients, regardless of whether they were asymptomatic (p < 0.05)or presented with mild (p < 0.0001) or moderate symptoms (p < 0.01). Anti-S IgG antibodies could be detected in participants up to 90 days post-infection. In conclusion, the lymphocyte levels in recovered patients were associated with the clinical presentation of the disease, and further analysis is required to investigate relationships between different clinical presentations and lymphocyte activation and function. |
format | Online Article Text |
id | pubmed-8040318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-80403182021-04-12 Prolonged humoral and cellular immunity in COVID-19-recovered patients() Alsayb, May A. Alsamiri, Ali Dakhilallah D. Makhdoom, Hatem Q. Alwasaidi, Turki Osman, Haitham Mohammed Mahallawi, Waleed H. Saudi J Biol Sci Original Article By the beginning of 2021, the battle against coronavirus disease 2019 (COVID-19) remains ongoing. Investigating the adaptive immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, in patients who have recovered from this disease could contribute to our understanding of the natural host immune response. We enrolled 38 participants in this study. 7 healthy participants and 31 COVID-19 patients who had recovered from COVID-19 and categorized them into 3 groups according to their previous clinical presentations: 10 moderate, 9 mild, and 12 asymptomatic. Flow cytometry analysis of peripheral lymphocyte counts in recovered patients showed significantly increased levels of CD4(+) T cells in patients with a history of mild and moderate COVID-19 symptoms compared with those healthy individuals (p < 0.05 and p < 0.0001 respectively). whereas no significant difference was observed in the CD8(+) T cell percentage in COVID-19-recovered patients compared with healthy individuals. Our study demonstrated that antibodies against the SARS-CoV-2 spike protein (anti-S) IgG antibody production could be observed in all recovered COVID-19 patients, regardless of whether they were asymptomatic (p < 0.05)or presented with mild (p < 0.0001) or moderate symptoms (p < 0.01). Anti-S IgG antibodies could be detected in participants up to 90 days post-infection. In conclusion, the lymphocyte levels in recovered patients were associated with the clinical presentation of the disease, and further analysis is required to investigate relationships between different clinical presentations and lymphocyte activation and function. Elsevier 2021-07 2021-04-12 /pmc/articles/PMC8040318/ /pubmed/33867805 http://dx.doi.org/10.1016/j.sjbs.2021.04.008 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Alsayb, May A. Alsamiri, Ali Dakhilallah D. Makhdoom, Hatem Q. Alwasaidi, Turki Osman, Haitham Mohammed Mahallawi, Waleed H. Prolonged humoral and cellular immunity in COVID-19-recovered patients() |
title | Prolonged humoral and cellular immunity in COVID-19-recovered patients() |
title_full | Prolonged humoral and cellular immunity in COVID-19-recovered patients() |
title_fullStr | Prolonged humoral and cellular immunity in COVID-19-recovered patients() |
title_full_unstemmed | Prolonged humoral and cellular immunity in COVID-19-recovered patients() |
title_short | Prolonged humoral and cellular immunity in COVID-19-recovered patients() |
title_sort | prolonged humoral and cellular immunity in covid-19-recovered patients() |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040318/ https://www.ncbi.nlm.nih.gov/pubmed/33867805 http://dx.doi.org/10.1016/j.sjbs.2021.04.008 |
work_keys_str_mv | AT alsaybmaya prolongedhumoralandcellularimmunityincovid19recoveredpatients AT alsamirialidakhilallahd prolongedhumoralandcellularimmunityincovid19recoveredpatients AT makhdoomhatemq prolongedhumoralandcellularimmunityincovid19recoveredpatients AT alwasaiditurki prolongedhumoralandcellularimmunityincovid19recoveredpatients AT osmanhaithammohammed prolongedhumoralandcellularimmunityincovid19recoveredpatients AT mahallawiwaleedh prolongedhumoralandcellularimmunityincovid19recoveredpatients |